Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis

NCT00633932 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00633932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00633932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
December 31, 2008
Enrollment
602 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

reflux esophagitis